Ranbaxy buys rights, assets for Senetek's autoinjector

New York, March 20 - Ranbaxy Laboratories Ltd.'s Ranbaxy Pharmaceuticals Inc. said it has bought the patents, trademarks and automated manufacturing equipment for Senetek plc's proprietary disposable autoinjector for self-administration of parenteral drugs, including epinephrine for emergency treatment of anaphylactic shock from peanut and other allergies.

Under the agreement, Ranbaxy will make a payment on signing and milestone payments based on regulatory approvals and cumulative sales milestones.

In addition, Senetek will receive a percentage of Ranbaxy's and/or its licensees' quarterly net sales.

Initially Ranbaxy will focus on pre-filling the autoinjector device with epinephrine. Ranbaxy will also evaluate the development of other parenteral drugs including Senetek's patented erectile dysfunction drug Invicorp.

Ranbaxy said it will make infrastructure investments, including building the required clean room suites at its facility in New Brunswick, N.J., to house the highly automated autoinjector production line.

Ranbaxy will obtain regulatory approvals and market the product. Ranbaxy has also agreed to discuss the possibility of manufacturing and supplying Invicorp in the autoinjector device to Senetek's licensees.

"Placing Senetek's autoinjector technology and equipment with a strong commercial partner committed to bringing it to market has been one of the key goals of Senetek's strategic plan," said Frank J. Massino, chairman and chief executive officer of Senetek, in a news release.

Ranbaxy, an India-based pharmaceutical company, produces generic drugs. Senetek is a Napa, Calif., life sciences-driven product development and licensing company focused on dermatological and skin care products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.